Pharmacokinetics of Insulin Detemir in Healthy Chinese Male Subjects

• Status: Completed
• Trial end date: 2007-09-01
• Target enrollment: 0
• Participant gender: Male

Summary

This trial is conducted in Asia. The aim of this trial is to investigate the pharmacokinetics after a single dose of insulin detemir in healthy Chinese male subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Insulin; Insulin Detemir; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• Body mass index (BMI) between 18 and 25 kg/m^2 (both inclusive)

• Fasting plasma glucose maximum 6 mmol/L

• Non-smoker

• Considered generally healthy upon completion of medical history, physical examination and laboratory assessments, as judged by the Investigator

Exclusion Criteria:

• Known or suspected allergy to trial product(s) or related products

• Previous participation in this trial. Participation is defined as randomisation

• Receipt of any investigational drug within the last three months prior to this trial

• History of alcohol or drug abuse